Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children-Reference-Cited by-同舟云学术

Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children

Published:2016 Issue:6 Volume:31 Page:950
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Cho Hye-Kyung¹²^ORCID,Park In Ho¹^ORCID,Burton Robert L.³,Kim Kyung-Hyo¹⁴^ORCID

Affiliation:

1. Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea.

2. Department of Pediatrics, Graduate School of Medicine, Gachon University, Incheon, Korea.

3. Departments of Pathology and Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.

4. Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea.

Funder

Ewha Womans University

Ministry of Food and Drug Safety

Publisher

Korean Academy of Medical Sciences

Subject

General Medicine

Link

http://synapse.koreamed.org/pdf/10.3346/jkms.2016.31.6.950

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033);Vaccine;2023-07

2. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1);Vaccine;2023-05

3. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2);Vaccine;2023-04

4. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis;Vaccine;2023-01

5. Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses;The Journal of Immunology;2021-04-02